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SHORT VERSION (i.e. removed several OH’s)  
Exometabolome characterisation of high cell density culture 
perfusion and optimization of the cell specific perfusion rate 
 
Véronique Chotteaua, Leila Zamania, Ye Zhanga, Caijuan Zhana, 
Magnus Abergb, Anna Lindhalc, Axel Miec, Pierre-Alain Girodd, 
Alexandra Martinéd 
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Very high cell density perfusion 
Four systems studied at CETEG (Cell Technology Group, KTH) 
Three different CHO cell lines, all producing MAb 
Wave	  brx;	  TFF-­‐MF;	  	  CHO#1;	  stable/Max	  	  
	  
Wave	  brx;	  	  ATF-­‐MF;	  CHO#1;	  Max	  
	  
Wave	  brx;	  	  TFF-­‐UF;	  	  CHO#1;	  Max	  
	  
Wave	  brx;	  	  ATF-­‐UF;	  	  CHO#1;	  Max	  
	  
STR	  brx;	  	  	  	  	  ATF-­‐MF;	  	  CHO#2;	  stable	  
	  
STR	  brx;	  	  	  	  	  ATF-­‐MF;	  	  CHO#2;	  stable/Max	  
	  
STR	  brx;	  	  	  	  	  ATF-­‐MF;	  	  CHO#3;	  stable/Max	  
	  
CellTank;	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  CHO#3;	  Max	  
	  
CellTank;	   	   	  	  	  CHO#3;	  stable	  
	  













0 10 20 30 40 




Wave bioreactor TFF-MF maintained & max 
ave bioreactor ATF MF max growth /CHO#1 
ave bioreactor TFF-UF max density /CHO#1 
ave bioreactor ATF-UF max density /CHO#1 
Glass bioreactor ATF maintained & max 
density /CHO#2 
ST  ATF-MF maintained density / CHO#2 
Glass bioreactor ATF-MF maintained & max 
density /CHO#3 
CellTank max density /CHO#2 








Nov 2,  2015 – Véronique Chotteau, CETEG, KTH – ECI-Continuous II, Berkeley 3 
Outline 
•  Exometabolome in perfusion culture  
•  Optimization of perfusion rate 
•  Conclusions 
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Study in WAVE Bioreactor™ in perfusion with TFF 
Goal 
•  Study of perfusion in Wave BioreactorTM 
•  Study of the limits of the system 
System 
•  Two types of cell separation based on hollow fiber filtration:  
•  Tangential flow filtration – TFF 
•  IgG production production in CHO cell system, CHO#1 
•  Application of cryopreservation / cell banking 
•  Working volume 4L 
•  Base medium supplemented by feed concentrate (Irvine Scientific, USA) 
CHO #1 
TFF 
Clincke et al 2013a, Clincke et al 2013b 
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Perfusion in WaveTM Bioreactor using TFF at very high cell 
densities 
viability (TFF) 
cell density (TFF) 
viability (ATF) 
cell density  
(ATF) 
Clincke et al 2013a, Clincke et al 2013b 
CHO cells at  
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Perfusion rate proportional to the cell density  
                              perfusion rate  
Cell Specific Perfusion Rate  where                         CSPR =  ___________________ 
                                cell density 
 
CSPR  =   50-60 pL/cell/day 
cell density (TFF) 
perfusion  
rate (TFF) 
Perfusion in WaveTM Bioreactor using TFF at very high cell 
densities 
CHO #1 































Exometabolome characterisation - Metabolomics in 
the culture supernatant in perfusion vs. fed-batch 
 
•  Purpose = Screening 
•  < 10 kDa fractions  
•  LC-MS: U-HPLC system (C18 column), coupled to 
an ESI-QTOF MS 
•  ≈ 10,000 peaks (intensity≥1,000) detected/sample 
è Data analyses 
•  Principal Component Analysis (PCA)  
à  Visualize the complex data set  
à  Identify similarities /differences between samples 
 
•  Partial Least Squares (PLS) regression  
à Identify relationships between the LC-MS data and 





























Collaboration: Stockholm Univ., Karolinska Institutet  
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PCA score plots based on positive and 
negative ion data for samples from 







•  Samples distributed 
according to time 
•  Longer distances between 




•  Samples not distributed 
according to time 
•  Shorter distances between 
the samples  
 
Fresh	  medium	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Score plot from data generated by PCA 
Modeling using fed-batch and perfusion data 
Model #A  
calibrated by data from 
fed-batch and perfusion 
runs 
CHO #1 
Model #B  
calibrated by data from fed-
batch runs only 
à  Perfusion and fresh 
medium predicted by the 
model 
à  clustering with days 3 to 
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Perfusion using ATF in stirred tank 
bioreactor 
 
Optimization of the perfusion rate  
CHO #2  CHO#3 
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Perfusion in stirred tank bioreactor with ATF 
Goal 
•  Better knowledge of the perfusion process à 
optimization 
System 
•  IgG production in CHO cell system,                  
CHO #2 (IgG#2), CHO#3 (IgG#3) 
 
•  Glass bioreactor - working volume 1L 
•  ATF2 (Refine) 
•  Control of perfusion by CytoSys (Iprabio) – 1 run 
•  Base medium supplemented by feed concentrate 
(Irvine Scientific, USA) 
Ye Zhang  Caijuan Zhan 
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•  High cell density with high viability 
•  Study of effect of CSPR 

















































































Perfusion in stirred tank bioreactor – Run #2 
•  Achievement of very high cell 
density with very high viability 
(> 92 %) 
Viability 































Viable	  cell	  density	  (106	  cells/mL)	  
Perfusion in stirred tank bioreactor – Run #2 
•  Volumetric productivity linear with cell 
density 
 
•  Volumetric productivity of 2 g/L/day at ≈ 
110 x 106 cells/mL vs. ≈ 2g/L obtained 
in a fed-batch for this cell line 
•  By-product levels not high 
Volumetric productivity 
CHO #2 
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Cell thaw from long-term perfusion 
Productivity test 
Preliminary data 
0,0	   0,2	   0,4	   0,6	  
μ	  (1/day)	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Conclusions 
•  Exometabolome foot printing in perfusion showing much higher consistency of the 
process from cell densities 10 to 200 x 106 cells/mL compared to fed-batch 
•  Observation of current metabolites confirmed by wide MS-based exometabolomics 
•  Identification of potential biomarkers for the cell density indicated glutathione 
metabolism modification towards higher cell densities 
•  Very high cell densities obtained in STR + ATF and other systems using CSPR 
•  IgG glycosylation not affected by high cell density up to 165 x 106 cells/mL and by low 
CSPR – Importance of CSPR for glycosylation 
•  CSPR minimized without affecting the cell health but lower IgG productivity 
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